Hikma opens new UK office to support NHS supply, strengthening European presence
London, 3 June 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announced the official opening of its commercial office in the UK, Hikma Pharmaceuticals International Limited (Hikma UK). Hikma will now directly supply NHS hospitals with injectable medicines across a broad range of therapeutic areas, reinforcing Hikma's long-standing commitment to the NHS.
Over the past eight years, Hikma has established itself as a trusted partner and critical supplier of injectable medicines to the NHS through a third-party partnership. Following the opening of this new commercial office, Hikma UK will now supply medicines to hospitals directly, leveraging its manufacturing facilities in Portugal, Italy, and Germany.
To date, Hikma has received 49 approvals and has launched 30 products (INN)1 in the UK.
Dr Bill Larkins, President of Hikma Injectables commented:
“The opening of the UK office, following our entry into Spain in May, is another significant milestone in our global strategy to expand our footprint across Europe. Our local presence, with manufacturing facilities in Portugal, Italy, and Germany, reduces supply chain complexities and enables us to provide NHS hospitals with direct and rapid access to essential injectable medicines.”
Daniel Green, Director, Commercial - UK and North Europe added:
“I'm excited to lead Hikma's dedicated commercial office in the UK. This demonstrates our ongoing commitment to supporting healthcare systems, including the NHS, by ensuring reliable access to high-quality and affordable injectable medicines.”
The Hikma UK Ltd office is co-located with the Hikma PLC office in London. For more information about Hikma UK, please go to https://www.hikma.com/en-uk/overview/.
1INN. name used to identify the active ingredient in a medicine. https://www.ema.europa.eu/en/glossary/international-non-proprietary-name